Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry

AHMET KARATAŞ
RABİA PİŞKİN SAĞIR
SÜLEYMAN SERDAR KOCA
HÜSEYİN EDİZ DALKILIÇ
GERÇEK CAN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
KARATAŞ, AHMET; SAĞIR, RABİA PİŞKİN; KOCA, SÜLEYMAN SERDAR; DALKILIÇ, HÜSEYİN EDİZ; CAN, GERÇEK; PEHLİVAN, YAVUZ; YAZICI, AYTEN; İNANÇ, GÜZİDE NEVSUN; ÇEFLE, AYŞE; ERTÜRK, ZEYNEP; AKAR, SERVET; ŞENEL, SONER; BİRLİK, AHMET MERİH; AKKOÇ, NURULLAH; and ÖNEN, FATOŞ (2023) "Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry," Turkish Journal of Medical Sciences: Vol. 53: No. 5, Article 33. https://doi.org/10.55730/1300-0144.5698
Available at: https://journals.tubitak.gov.tr/medical/vol53/iss5/33

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry

Authors

AHMET KARATAŞ, RABİA PİŞKİN SAĞIR, SÜLEYMAN SERDAR KOCA, HÜSEYİN EDİZ DALKILIÇ, GERÇEK CAN, YAVUZ PEHLİVAN, AYTEN YAZICI, GÜZİDE NEVSUN İNANÇ, AYŞE ÇEFLE, ZEYNEP ERTÜRK, SERVET AKAR, SONER ŞENEL, AHMET MERİH BİRLİK, NURULLAH AKKOÇ, and FATOŞ ÖNEN

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol53/iss5/33
Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry

Ahmet KARATAŞ1, Rabia PIŞKIN SAGIR2,3*, Süleyman Serdar KOÇA1, Ediz DALKILIÇ4, Gerçek CAN1, Yavuz PEHLİVAN1, Ayten YAZICI1, Nevsun İNANÇ1, Ayşe ÇEFLE1, Zeynep ERTÜRK2, Servet AKAR1, Soner ŞENEL1, Merih BİRLİK1, Nurullah AKKOÇ4, Fatoş ÖNEN6

1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Firat University, Elazığ, Türkiye
2Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uludağ University, Bursa, Türkiye
3Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye
4Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, İzmit, Türkiye
5Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Marmara University, İstanbul, Türkiye
6Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Medipol University, İstanbul, Türkiye
7Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Katip Celebi University, İzmir, Türkiye
8Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Türkiye
9Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Celal Bayar University, Manisa, Türkiye

Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to determine whether the body mass index (BMI) is involved in the response to rituximab in rheumatoid arthritis (RA).

Materials and methods: This multicenter retrospective study included 206 RA patients who received rituximab from the Turkish Biologic (TURKBİO) registry between 2011 and the end of May 2017. Demographic and clinical data including age, sex, disease type, disease duration, and previous or current treatment with disease-modifying antirheumatic drugs (DMARDs) and biological drug durations are stored in the database. Patients with a BMI ≥30 kg/m² were classified as obese, and patients with a BMI <30 kg/m² were classified as nonobese. Kaplan-Meier survival analysis was performed to estimate the drug survival. The subgroups were compared using the log-rank test.

Results: The mean BMI of 206 patients included in the study was 27.05 (17.2–43.4) kg/m². There were 59 (28.6%) patients in the obese group and 147 (71.4%) patients in the nonobese group. The mean age, female percentage, and baseline disease activity score 28 (DAS28) were higher in the obese group than in the nonobese group. However, the ΔDAS28 at both 6 and 12 months were not significantly different between the groups (p = 0.785 and p = 0.512, respectively). Patient pain Visual Analogue Scale (VAS), patient fatigue VAS, and patient global VAS scores were also significantly higher at baseline in the obese group (p = 0.003, p = 0.006, and p = 0.006, respectively). However, no significant difference was found in terms of changes in patient pain VAS, patient fatigue VAS, patient global VAS and physician global VAS scores at 6 and 12 months compared to those at baseline. Rituximab treatment was ongoing for 71.2% of the obese and 63.3% of the nonobese patients (p = 0.279). The median drug survival duration was 77 months in the obese group and 62 months in the nonobese group (p = 0.053). The estimated drug survival rates for rituximab were not statistically significantly different in the obese and nonobese groups. Rituximab-related side effects were also similar between the groups.

Conclusion: In obese and nonobese patients with RA, rituximab treatment exhibits similar side effects and similar long-term efficacy. These results suggest that obesity does not alter drug survival for rituximab and response rates, in RA and rituximab may be a favorable treatment agent in patients with RA and obesity.

Key words: Body mass index, drug survival, obesity, rheumatoid arthritis, rituximab

1. Introduction

Obesity, which plays a role in many chronic systemic diseases and sudden cardiac death in young individuals, is a serious disease for the community [1, 2]. Research on obesity has increased over the last few years due to the increased prevalence of obesity and increased risk of obesity-related illnesses [3]. It is understood that white adipose tissue has been associated with systemic

* Correspondence: piskinrabia@hotmail.com
inflammation in the past 10 years [4,5]. In addition, white fat tissue behaves like an endocrine active organ. Adipose tissue is involved not only in metabolism but also in the immune system and inflammatory processes through pro-inflammatory mediators and adipocytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, adiponectin, leptin, resistin, visfatin, and C-reactive protein (CRP) [6].

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease [7] and obesity is seen in 18%-31% of patients with RA and slightly higher than the general population. Almost 60% of patients with RA appear to be overweight [8, 9]. The relationship of obesity on the presence of RA and disease activity is still unclear [10,11]. In the early stages of RA, obesity may slow the progression of the disease [12]. However, obesity can increase disease activity and disability in patients with advanced RA [13]. In a large retrospective case-control study, obesity was found to cause a modest increase in risk for RA development in patients [14]. Additionally, studies in different patient cohorts have shown that obesity is associated with seronegative RA in females [15].

Considering the fact that RA is a progressive disease, the accumulation of joint damage can cause irreversible disability if left untreated or even improperly treated. Numerous RA patients all over the world are treated with conventional agents, such as glucocorticoids and methotrexate (MTX) [16]. Nonetheless, some patients may not tolerate them or even may not achieve disease remission. Although the etiology and the pathogenesis of RA are complex, different newly employed biologics have revolutionized therapeutic approaches. They usually suppress the immune system by targeting particular signaling pathways and act in a more specific manner. It was suggested that biologic agents, such as TNFα inhibitors and rituximab could significantly reduce mortality risk in RA patients compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [17]. Rituximab, a chimeric anti-CD20 monoclonal antibody, depletes B cells through different mechanisms, including the apoptosis of B cells, complement-dependent cytotoxicity, and mediation of antibody-dependent cellular cytotoxicity [18]. Generally, rituximab administration in RA patients has been accepted as a safe procedure, and prolonged exposure to rituximab does not seem to be related to additional adverse events. However, there are some increasing concerns related to the safety profiles of rituximab in RA patients, such as the development/reactivation of infections, failure of immunization, and paradoxical reactions [19].

Patients with a body mass index (BMI) >30 kg/m² are considered as obese. Pharmacokinetic variables such as drug clearance and distribution volume can be affected by obesity [20]. Several previous reports have documented that obesity decreases the response rate to anti-TNF-α agents in RA [21, 22]. Therefore, it is thought that adipose tissue has effects in the treatment of biologic agents, and obesity affects the course of the disease and the response to antirheumatic agents in RA [21, 22].

Since previous studies have documented that obesity reduces the response rate to anti-TNF-α agents in RA, the aim in this study was to determine whether BMI affects the response to rituximab in RA.

2. Materials and methods
The Turkish Biologic (TURKBIO) database is the Turkish version of the Danish DANBIO rheumatology database established in 2011. This database collects demographic and clinical data such as age, sex, disease type, disease duration, disease activity, previous or current treatment and biological drug use duration from patients with RA receiving biological treatment at several tertiary rheumatology centers across the country. Ethics committee approval was obtained for this database and the study from the Turkish Medicines and Medical Devices Agency of the Ministry of Health dated 25/07/2013 under number 26247029-514-05-01. This multicenter retrospective study included 206 patients enrolled in the TURKBIO database who met the American College of Rheumatology/European League Against Rheumatism 2010 Rheumatoid Arthritis Classification criteria [23], receiving standard doses of 1000 mg rituximab on days 0 and 15 between 2011 and the end of May 2017.

Demographic data prior to rituximab treatment, disease duration, BMIs (the BMIs of the patients at the time of registration in the TURKBIO database), medications received before rituximab treatment, disease activity indices at baseline, and 6 and 12 months of rituximab treatment [disease activity score 28 (DAS28)], Health Assessment Questionnaire (HAQ) scores, Visual Analogue Scale (VAS) scores (including the patient pain VAS, patient fatigue VAS, patient global VAS, and physician global VAS scores), erythrocyte sedimentation rates (ESR), CRP level, and whether the patients were continuing rituximab treatment were recorded. Patients with a BMI ≥30 kg/m² were classified as obese, and patients with a BMI <30 kg/m² were classified as nonobese [2].

3. Statistics
Predictive Analytics for Windows 18.0 (Chicago, IL, USA) was used for the statistical analysis. The continuous variables were presented as either the mean ± SD or median (min–max or IQR) according to data distribution normality and the categorical variables were presented as numbers (%). Kaplan-Meier survival analysis was used for the descriptive statistics to determine the drug use rates,
and the log-rank test was used to determine the difference between the BMI groups. The chi squared test was used for the categorical variables, and Fisher exact test was used where the chi squared test was not applicable. The Mann-Whitney U test was used for the numerical variables when the data were not normally distributed. Cases in which the type-1 error level was <5% were interpreted as statistically significant.

4. Results

4.1. Demographic and baseline characteristics

There were 157 (76.2%) female and 49 (23.8%) male patients, and the mean age was 58 (21–85) years. The mean disease duration was 12 (2–36) years. Hypertension was the most prevalent comorbidity (33.6%), followed by osteoporosis, diabetes, depression, asthma, cardiovascular diseases, kidney diseases, chronic bronchitis, liver diseases, tuberculosis, and cancer. The mean BMI of the patients included in the study was 27.05 (17.2–43.4) kg/m². There were 59 (28.6%) patients in the obese group and 147 (71.4%) patients in the nonobese group. The smoking history of 162 patients included in the study was known, 92 patients (56.8%) had never smoked, 36 patients (22.2%) had quit, and 34 patients (21%) were still smoking.

Rheumatoid factor and anticyclic citrullinated peptide antibodies were positive in 81.4% and 75.2% patients, respectively, and 158 (76.6%) patients were receiving combination treatment with rituximab. Of these patients, 91 (44.2%) were using MTX and 67 (32.5%) were using leflunomide combination treatments. When the biological naïveté was evaluated, it was revealed that 152 patients had previous exposures to at least 1 biological agent, and the most commonly used biological agent was etanercept, at a rate of 25.7% (53 patients). There was no difference in the use of concomitant csDMARDs or previous biological treatments between the obese and nonobese groups.

The mean duration of rituximab treatment was 37 (2–150) months. While 135 patients (65.5%) continued treatment, 71 (34.5%) had discontinued. The lack of effectiveness was the most frequently reported reason for discontinuing treatment, and treatment was discontinued in 24 patients for this reason. Only 10 of the treated patients experienced side effects, of whom 4 had to discontinue treatment due to major side effects. The reasons for the patients to discontinue using the rituximab are shown in Table 1.

The median ESR was 32 (1–100) mm/h, CRP was 9 (0–87) mg/dL, total DAS28 was 4.45 (1.7–7.1), HAQ score was 1.2 (0–2.88), patient pain VAS score was 60 (0–100), patient fatigue VAS score was 50.5 (0–100), patient global VAS score was 60 (0–100) and physician global VAS score was 50 (0–90).

Baseline demographic, clinical, and laboratory data according to the BMI status of the patients are presented in the Table 2. The mean age and percentage of females were higher in the obese group. The difference in the smoking status between the BMI groups was statistically significant. The proportion of patients still smoking was low in the obese group (p = 0.007). Investigation of the baseline disease activity indicators showed that the DAS28 and patient pain VAS, patient fatigue VAS and patient global VAS scores were significantly higher in the obese group (p = 0.02, p = 0.003, p = 0.006, and p = 0.006, respectively). No difference was found in terms of the other parameters (Table 2).

4.2. Changes in disease activity with rituximab treatment

The values of the patients at baseline and 6 and 12 months, as well as the Δchange values at 6 and 12 months are presented in the Table 3. The DAS28 score was significantly higher in the obese group at baseline and 6 months (p = 0.02, p = 0.04, respectively). However, the ΔDAS28 scores at both 6 and 12 months were not significantly different.
between the groups (p = 0.785 and p = 0.512, respectively). The patient pain VAS, patient fatigue VAS, and patient global VAS scores were also significantly higher at baseline in the obese group (p = 0.003, p = 0.006, and p = 0.006, respectively). However, no significant difference was found in terms of changes in the patient pain VAS, patient fatigue VAS, patient global VAS, and physician global VAS scores at 6 and 12 months compared to those at baseline (p = 0.431, p = 0.971, p = 0.51, and p = 0.625 for changes in the scores between baseline and 6 months; p = 0.838, p = 0.463, p = 0.984, and p = 0.355 for changes in the scores between baseline and 12 months). Patients with obesity treated with rituximab had a greater decrease in delta CRP levels between baseline and 6 months than patients without obesity (p = 0.031).

### 4.3. Treatment retention rates

The mean duration of rituximab use was 39 (2–111) months in the obese group and 36 (2–150) months in the nonobese group (p = 0.105). In addition, 71.2% of the obese patients and 63.3% of the nonobese patients continued treatment (p = 0.279). Looking at the percentage of patients who continued treatment at year 1 and year 5, 100% of the obese patients and 99.5% of the nonobese patients continued treatment in year 1. However, the 5-year evaluation showed that 67.5% of the obese group and 52.8% of the nonobese group continued treatment. Lack of effectiveness was the main reason for discontinuing treatment in both groups, and there was no significant difference between the groups. Rituximab-related side effects were also similar between the groups. The median duration of drug use was higher in the obese group (77 months) than in the nonobese group (62 months) (p = 0.053); however, this difference was not statistically significant (Figure).

### 5. Discussion

The results of this study showed that only 32.5% of the patients were of normal weight (BMI <25) and 28.6% were obese (BMI ≥30), and the burden of disease was higher in the patients with obesity. Furthermore, the findings revealed that drug survival and response rates for rituximab in RA treatment do not change in the presence of obesity. Giving the appropriate treatment to the appropriate patient is important to provide cost-effective care and prevent morbidity and mortality of the disease. The patient's response to treatment is affected by numerous factors, and the impact of obesity, which is a serious health problem, on both disease occurrence and treatment response have been investigated in studies. The results from 2 large prospective cohort studies showed an increased risk for developing both seropositive and seronegative RA in patients with obesity. Interestingly, the duration of obesity was also found to be associated with this risk [24]. In the current study, only 67 (32.5%) patients with RA had
Table 3. Comparison of the disease activity indices at baseline, 6 months and 12 months.

<table>
<thead>
<tr>
<th></th>
<th>Obese patients (n = 59)</th>
<th>Nonobese patients (n = 147)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESR at baseline (mm/h)</strong></td>
<td>34 (13–84)</td>
<td>32 (1–100)</td>
<td>0.199</td>
</tr>
<tr>
<td><strong>ESR at 6 months (mm/h)</strong></td>
<td>28 (5–73)</td>
<td>27 (2–110)</td>
<td>0.913</td>
</tr>
<tr>
<td><strong>ESR at 12 months (mm/h)</strong></td>
<td>25 (8–50)</td>
<td>28 (2–94)</td>
<td>0.980</td>
</tr>
<tr>
<td><strong>Δ_ESR (mm/h)</strong></td>
<td>–17.5 (–46 to 11)</td>
<td>–4 (–45 to 29)</td>
<td>0.114</td>
</tr>
<tr>
<td><strong>Δ_ESR (mm/h)</strong></td>
<td>–2 (–48 to 11)</td>
<td>–4 (–40 to 32)</td>
<td>0.686</td>
</tr>
<tr>
<td><strong>CRP at baseline (mg/dL)</strong></td>
<td>10.5 (2–75)</td>
<td>8.5 (0–87)</td>
<td>0.383</td>
</tr>
<tr>
<td><strong>CRP at 6 months (mg/dL)</strong></td>
<td>6 (2–70)</td>
<td>6 (0–105)</td>
<td>0.673</td>
</tr>
<tr>
<td><strong>CRP at 12 months (mg/dL)</strong></td>
<td>4.14 (3–27)</td>
<td>4 (0.9–46.3)</td>
<td>0.903</td>
</tr>
<tr>
<td><strong>Δ1_CRP (mg/dL)</strong></td>
<td>–10 (–67 to 4)</td>
<td>0 (–69 to 67)</td>
<td>0.031</td>
</tr>
<tr>
<td><strong>Δ2_CRP (mg/dL)</strong></td>
<td>–3 (–38 to 19)</td>
<td>0 (–54.7 to 28.3)</td>
<td>0.354</td>
</tr>
<tr>
<td><strong>DAS28 at baseline</strong></td>
<td>4.8 (2–7.1)</td>
<td>4.3 (1.7–6.6)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>DAS28 at 6 months</strong></td>
<td>3.4 (1.7–5.6)</td>
<td>2.7 (1.2–5.8)</td>
<td>0.045</td>
</tr>
<tr>
<td><strong>DAS28 at 12 months</strong></td>
<td>3 (1.5–8)</td>
<td>2.5 (1.2–5.8)</td>
<td>0.274</td>
</tr>
<tr>
<td><strong>Δ1_DAS28</strong></td>
<td>–1.6 (–4.4 to 0.4)</td>
<td>–0.9 (–4 to 0)</td>
<td>0.785</td>
</tr>
<tr>
<td><strong>Δ2_DAS28</strong></td>
<td>–1.95 (–5.4 to 0.8)</td>
<td>–1.4 (–34 to 0.7)</td>
<td>0.512</td>
</tr>
<tr>
<td><strong>HAQ at baseline</strong></td>
<td>1.15 (0.25–2.88)</td>
<td>1.25 (0–2.88)</td>
<td>0.869</td>
</tr>
<tr>
<td><strong>HAQ at 6 months</strong></td>
<td>0.75 (0–2.13)</td>
<td>0.57 (0–2.88)</td>
<td>0.633</td>
</tr>
<tr>
<td><strong>HAQ at 12 months</strong></td>
<td>0.75 (0–1.38)</td>
<td>0.63 (0–2.75)</td>
<td>0.826</td>
</tr>
<tr>
<td><strong>Δ1_HAQ</strong></td>
<td>–0.25 (–1.87 to 0.98)</td>
<td>–0.38 (–2.75 to 1.5)</td>
<td>0.674</td>
</tr>
<tr>
<td><strong>Δ2_HAQ</strong></td>
<td>–0.31 (–1.25 to 0)</td>
<td>–0.19 (–2.75 to 0.38)</td>
<td>0.338</td>
</tr>
<tr>
<td><strong>Patient pain VAS at baseline</strong></td>
<td>75 (40–100)</td>
<td>52 (0–100)</td>
<td>0.003</td>
</tr>
<tr>
<td><strong>Patient pain VAS at 6 months</strong></td>
<td>48 (8–80)</td>
<td>30.5 (0–100)</td>
<td>0.353</td>
</tr>
<tr>
<td><strong>Patient pain VAS at 12 months</strong></td>
<td>45 (0–80)</td>
<td>39 (0–80)</td>
<td>0.486</td>
</tr>
<tr>
<td><strong>Patient pain Δ_VAS</strong></td>
<td>–30 (–59 to 2)</td>
<td>–30 (–85 to 11)</td>
<td>0.431</td>
</tr>
<tr>
<td><strong>Patient pain Δ_VAS</strong></td>
<td>–27.5 (–75 to 30)</td>
<td>–33 (–70 to 50)</td>
<td>0.838</td>
</tr>
<tr>
<td><strong>Patient fatigue VAS at baseline</strong></td>
<td>68 (0–90)</td>
<td>50 (0–100)</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>Patient fatigue VAS at 6 months</strong></td>
<td>50 (4–71)</td>
<td>40.5 (0–100)</td>
<td>0.285</td>
</tr>
<tr>
<td><strong>Patient fatigue VAS at 12 months</strong></td>
<td>40 (10–79)</td>
<td>36.5 (0–100)</td>
<td>0.739</td>
</tr>
<tr>
<td><strong>Patient fatigue Δ_VAS</strong></td>
<td>–20 (–58 to 1)</td>
<td>–20 (–95 to 28)</td>
<td>0.971</td>
</tr>
<tr>
<td><strong>Patient fatigue Δ_VAS</strong></td>
<td>–32.5 (–75 to 16)</td>
<td>–20 (–60 to 43)</td>
<td>0.462</td>
</tr>
<tr>
<td><strong>Patient global VAS at baseline</strong></td>
<td>72 (21–100)</td>
<td>50 (0–100)</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>Patient global VAS at 6 months</strong></td>
<td>47 (5–70)</td>
<td>49.5 (0–86)</td>
<td>0.791</td>
</tr>
<tr>
<td><strong>Patient global VAS at 12 months</strong></td>
<td>50 (0–80)</td>
<td>30 (0–82)</td>
<td>0.374</td>
</tr>
<tr>
<td><strong>Patient global Δ_VAS</strong></td>
<td>–20 (–55–0)</td>
<td>–30 (–86 to 40)</td>
<td>0.51</td>
</tr>
<tr>
<td><strong>Patient global Δ_VAS</strong></td>
<td>–20 (–75 to 30)</td>
<td>–30 (–80 to 40)</td>
<td>0.984</td>
</tr>
<tr>
<td><strong>Physician global VAS at baseline</strong></td>
<td>61.5 (6–90)</td>
<td>50 (0–90)</td>
<td>0.121</td>
</tr>
<tr>
<td><strong>Physician global VAS at 6 months</strong></td>
<td>27.5 (10–54)</td>
<td>20 (0–63)</td>
<td>0.092</td>
</tr>
<tr>
<td><strong>Physician global VAS at 12 months</strong></td>
<td>20 (0–70)</td>
<td>13 (0–68)</td>
<td>0.612</td>
</tr>
<tr>
<td><strong>Physician global Δ_VAS</strong></td>
<td>–43 (–63 to 4)</td>
<td>–32.5 (–80 to 20)</td>
<td>0.625</td>
</tr>
<tr>
<td><strong>Physician global Δ_VAS</strong></td>
<td>–47.5 (–85 to 0)</td>
<td>–40 (–90 to 28)</td>
<td>0.355</td>
</tr>
</tbody>
</table>

Data are expressed as the median (min–max). Δ₁ reflects the changes between baseline and 6 months. Δ₂ reflects the changes between baseline and 12 months.
a BMI <25 kg/m² and were not obese or overweight. Since obesity is the cause of RA, it may be commonly observed in patients with RA. However, to the best of our knowledge, there are no studies in the literature showing that RA causes obesity, and corticosteroid treatment as well as the restriction of physical activities due to active arthritis may also be the reason for the more frequent incidence of obesity in patients with RA. With the understanding that obesity increases the risk of developing RA, whether it affects treatment response has also been investigated. Studies have shown that in addition to being a common comorbid condition, obesity causes the disease to worsen and also affects the treatment response to several agents [25]. Higher DAS28, patient pain VAS, patient fatigue VAS, and patient global VAS scores, which are among the pretreatment disease activity indicators, found in the obese group in the current study were in line with the literature. In a study by Colmegna et al. involving 200 patients with RA, the HAQ, DAS-28, and tender joint scores were higher in the obese group compared to those in the nonobese group [26]. Similarly, a study by Sandberg et al. that evaluated whether the presence of obesity at the time of diagnosis affects disease activity in the early stage of RA found higher DAS scores in patients with obesity [25]. In addition to the biological change caused by obesity, in the study by Sommers et al. [27], they observed that the pain threshold of patients with RA and obesity was lower, and the patients felt more desperate in the presence of pain. This may lead to higher DAS scores due to the low self-confidence of the patients in both managing arthritis and losing weight [27].

Since proinflammatory cytokines, including TNF and IL-6, are secreted by white adipose tissue, it is thought that excess adipose mass in patients with RA and obesity may affect treatment response by increasing the level of these cytokines [28]. Indeed, in a study by Schäfer et al. on patients with RA that investigated the relationship between obesity and response to conventional synthetic and biological DMARDs, it was seen that obesity reduced the efficacy of cytokine-targeted treatments such as TNF inhibitor and tocilizumab treatments, whereas such decreased efficacy was not observed for therapeutic agents targeting immune cells, such as rituximab and abatacept treatments [29]. However, in another retrospective study conducted by Pers et al., treatment responses after 6 months of tocilizumab use were not affected by the BMI [30]. A French study including 115 patients with RA who received tocilizumab found that treatment responses were not different between the BMI groups [31]. On the other hand, it was shown in an experimental study by
Crouch et al. that obesity inhibits B cell development [32].
Both increased cytokine secretion and decreased B cell development in obesity may be the reason for the lack of effectiveness of rituximab treatment.

A study on 19,372 patients with immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD), RA, spondyloarthopathies, psoriasis, and psoriatic arthritis, examined whether obesity affects response to anti-TNF agents. In that study, the treatment failure rate was 60% higher in the patients with obesity, but while this difference was seen in the patients with rheumatic diseases, it was not seen in those with IBD [33]. Again, in a study evaluating the efficacy of TNF inhibitor in the obese group among patients with ankylosing spondylitis, RA and psoriatic arthritis patients, a negative correlation was found between the BMI and response to anti-TNF treatments [22, 34, 35]. However, to date, the effect of anti-TNF agents on adipokine levels remains unclear. It is known that the pharmacokinetics of infliximab (IFX), an intravenously administered nonlipophilic anti-TNF molecule, may change in the presence of excess adipose tissue. Therefore, it can be thought that the distribution volume of a nonlipophilic drug such as IFX may be reduced due to the presence of excess adipose tissue, and this may partially explain its limited effect in patients with obesity compared to the effect of other subcutaneously administered anti-TNF agents (etanercept and adalimumab). However, in the same study, although the number of patients was limited, a high BMI did not show any adverse effects on treatment and clinical responses in 114 patients with RA receiving rituximab. Although rituximab is a nonlipophilic drug similar to IFX, the increase in adipose tissue had no impact on drug pharmacokinetics and rituximab distribution [36]. Although there are various studies showing that the efficacy of anti-TNF agents decreases in patients with obesity, no adverse outcomes were reported with rituximab treatment, similar to the presents study.

Since this study was retrospective registry data, it is not easy to find and present all the data of the patients, but it is important that this study was based on real-life data. However, the lack of power analysis was a limitation of the study, and all of the patients enrolled in a certain time interval were included in the study. In addition, another limitation of the study was that the patients had BMIs recorded at the time they were registered in the TURKBIO database, and their BMIs at the beginning or end of rituximab treatment were not known.

In conclusion, obesity is common in patients with RA, and obesity leads to a greater disease burden. In obese and nonobese patients with RA, rituximab treatment exhibits similar side effects and similar long-term efficacy. These results suggest that the long-term efficacy of rituximab treatment is not affected by obesity in patients with RA, and rituximab may be a favorable treatment agent in patients with RA and obesity. Nonetheless, these data should be further investigated in prospective case-control studies.

References


